降钙素基因相关肽在偏头痛胃肠道症状中的作用:临床考量——一篇叙述性综述
本叙述性综述总结了偏头痛与胃肠道疾病关联的流行病学证据,探讨了降钙素基因相关肽(CGRP)在这些关联中可能的生理作用,并回顾了接受CGRP靶向治疗及其他偏头痛治疗的患者中胃肠道事件的临床发生情况,进而提出了一种减轻这些影响的患者管理策略。
要点
- CGRP参与偏头痛发作的多个病理生理过程,并作用于胃肠道伤害感受、炎症、胃酸分泌和动力。
- 偏头痛患者可能共病功能性上、下消化道疾病,如胃食管反流病、胃轻瘫、功能性腹泻或便秘及肠易激综合征。
- 偏头痛的胃肠道症状可能与治疗相关,也可能归因于CGRP升高;作者提出了一种管理策略以减轻这些影响。
核心结论
- CGRP在偏头痛的胃肠道症状中可能起作用,偏头痛患者共病和治疗相关胃肠道效应风险增加,作者提出了一种患者管理策略以减轻这些影响。
研究设计与样本
- 叙述性综述,总结了偏头痛与胃肠道疾病关联的流行病学证据、CGRP可能的生理作用,并回顾了CGRP靶向治疗及其他偏头痛治疗中胃肠道事件的临床发生情况。
主要发现
- 靶向CGRP或其受体的治疗已显示对偏头痛的预防或急性治疗有效。
- 两种小分子CGRP受体拮抗剂(rimegepant和ubrogepant)获批用于偏头痛的急性治疗,四种单克隆抗体(eptinezumab、erenumab、fremanezumab和galcanezumab)获批用于偏头痛预防;erenumab靶向经典CGRP受体,其余靶向CGRP配体。
- CGRP在胃肠道伤害感受、炎症、胃酸分泌和动力中起作用。
- 恶心和呕吐是偏头痛相关的胃肠道症状,但偏头痛个体也可能经历功能性上、下消化道共病,如胃食管反流病、胃轻瘫、功能性腹泻或便秘及肠易激综合征。
- 偏头痛的胃肠道症状可能与治疗相关,也可能归因于CGRP升高。
临床怎么用
- 作者提出了一种患者管理策略以减轻偏头痛患者共病和治疗相关胃肠道效应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Calcitonin gene-related peptide (CGRP) is involved in several of the pathophysiologic processes underpinning migraine attacks. Therapies that target CGRP or its receptor have shown efficacy as preventive or acute treatments for migraine. Two small-molecule CGRP receptor antagonists (rimegepant and ubrogepant) are approved for the acute treatment of migraine, and 4 monoclonal antibodies (eptinezumab, erenumab, fremanezumab, and galcanezumab) are approved for migraine prevention; erenumab targets the canonical CGRP receptor, the others CGRP ligand. CGRP plays a role in gastrointestinal nociception, inflammation, gastric acid secretion, and motility. Nausea and vomiting are among the gastrointestinal symptoms associated with migraine, but individuals with migraine may also experience functional upper and lower gastrointestinal comorbidities, such as gastroesophageal reflux disease, gastroparesis, functional diarrhea or constipation, and irritable bowel syndrome. Although gastrointestinal symptoms in migraine can be treatment-related, they may also be attributable to increased CGRP. In this review, we summarize the epidemiologic evidence for associations between migraine and gastrointestinal disorders, consider the possible physiologic role of CGRP in these associations, and review the clinical occurrence of gastrointestinal events in patients with migraine receiving CGRP-based therapies and other migraine treatments. Because patients with migraine are at an increased risk of comorbid and treatment-related gastrointestinal effects, we also propose a patient-management strategy to mitigate these effects.
引用
- Ailani J, Kaiser EA, Mathew PG, et al. Role of Calcitonin Gene-Related Peptide on the Gastrointestinal Symptoms of Migraine-Clinical Considerations: A Narrative Review. Neurology. 2022. PMID: 36127137. doi:10.1212/WNL.0000000000201332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。